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A B S T R A C T
Introduction: Sub-optimal use or interpretation of imaging investigations prior to diagnosis of certain cancers
may be associated with less timely diagnosis, but pre-diagnostic imaging activity for urological cancer is un-
known.
Method: We analysed linked data derived from primary and secondary care records and cancer registration to
evaluate the use of clinically relevant imaging tests pre-diagnosis, in patients with bladder and kidney cancer
diagnosed in 2012-15 in England. As pre-diagnostic imaging activity increased from background rate 8 months
pre-diagnosis, we used logistic regression to determine factors associated with first imaging test occurring 4–8
months pre-diagnosis, considering that such instances may reflect possible missed opportunities for expediting
the diagnosis.
Results: 1963 patients with bladder or kidney cancer had at least one imaging test in the 8 months pre-diagnosis.
420 (21%) of patients had their first imaging test 4–8 months pre-diagnosis, that being ultrasound, CT and X-ray
in 48%, 43% and 9% of those cases, respectively. Factors associated with greater risk of a first imaging test 4–8
months pre-diagnosis were kidney cancer, diagnosis at stages other than stage IV, first imaging having been an X-
ray, test requested by GP and absence of haematuria before the imaging request.
Conclusion: About 1 in 5 patients with urological cancers receive relevant first imaging investigations 4–8
months prior to diagnosis, which may represent potential missed diagnostic opportunities for earlier diagnosis.
1. Introduction
Timely diagnosis of cancer is associated with better clinical and
patient reported outcomes [1,2]. In the United Kingdom (UK), a
number of early diagnosis initiatives have been implemented over the
last 12 years [3].
Patterns of pre-diagnostic healthcare utilisation may indicate op-
portunities for expediting the diagnosis of cancer; these could include
increase in the background rate of consultations, prescriptions and la-
boratory test use, long before the immediate pre-diagnosis period
[4–11]. While it is plausible that the rate of imaging activity could also
increase long before the diagnosis of cancer [12,13], we are unaware of
such evidence in patients with bladder and kidney cancer. Such events
may represent missed opportunities for more timely diagnosis of
cancer. Possible scenarios include: normal findings leading to ‘false
reassurance’ and diagnostic closure where investigations ought to have
continued; and abnormal findings either not being appropriately en-
acted upon, scheduling delays or other system factors delaying planned
subsequent assessment [14].
In the UK, about 10,000 and 12,500 patients are diagnosed with
bladder and kidney cancer respectively every year (hereafter referred to
as urological cancer, unless otherwise specified) [15]. While a small
proportion of small kidney cancers diagnosed via imaging might re-
present incidental findings in asymptomatic individuals [16], imaging
tests such as ultrasound or computed tomography (CT) have a role in
investigating symptomatic patients with suspected urological cancer
[17–20]. Although general practitioners (GPs) may have direct access
to some imaging tests (such as ultrasound), delays relating to the
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scheduling, performing and reporting of these tests may occur.
Given this background, we aimed to describe the patterns of pre-
diagnostic imaging test use and predictors of a first imaging test in
bladder and kidney cancer patients occurring several months pre-di-
agnosis. This type of analysis could help estimate the frequency of
possible missed opportunities related to the use of imaging investiga-
tions for a more timely diagnosis of urological cancer, and factors that
may be associated with them.
2. Methods
2.1. Data sources
We used primary care data from the Clinical Practice Research
Datalink (CPRD) that provides patient-level linkage to data from the
National Cancer Registration Analysis Services (NCRAS), Hospital
Episode Statistics Diagnostic Imaging Dataset (HES DID) and Index of
Multiple Deprivation quintiles (deprivation indices defined for small
geographies) [21].
The CPRD contains primary care data from about 7% of GP practices
in England, Wales and Scotland, with coverage that is approximately
representative of the UK population [22]. About 75% of practices in
England have consented to data linkage with other data sets and our
study is restricted to those practices [22]. NCRAS data contains detailed
tumour level information, including cancer site and date of diagnosis.
HES DID contains imaging tests that are performed in English National
Health Service (NHS) hospitals, including information on imaging
modality, imaged body sites, referral source (e.g. primary/specialist
care) and date, referral receipt date, and imaging and reporting dates.
2.2. Study population
A comprehensive list of Read diagnosis codes for bladder and kidney
cancer were provided to CPRD to extract the cohort, concordant with
prior literature [23,24]. Included patients were aged 25 years and over
at diagnosis of cancer, with a first-ever recorded bladder or kidney
cancer between 1st April 2012 and 31st December 2015. We supple-
mented CPRD cases with additional cases identified using ICD-10
cancer codes from NCRAS only, and used the NCRAS diagnosis and date
where discrepancies existed. Cancers were sub-divided into bladder,
kidney or upper urinary tract urothelial cell cancer.
2.3. Imaging types
We used the National Interim Clinical Imaging Procedure codes to
determine all imaging tests performed in our patient cohort in the 12
months before their cancer diagnosis. Although information was
available on seven modalities (x-ray, ultrasound, computed tomo-
graphy (CTs), magnetic resonance imaging (MRI), fluoroscopy, image-
guided endoscopy and nuclear medicine) hereafter we focus on X-ray,
ultrasound and CT imaging events, as the most relevant modalities for
investigation of possible urological cancer and as use of other mod-
alities in our cases was very infrequent.
A clinician (YZ) grouped each imaging modality by body site into a)
urinary tract-related, b) abdomen (without specific mention of urinary
tract organs), and c) other body sites. Imaging tests for other body sites
were a priori excluded to minimise potential bias for requests for un-
related reasons, particularly regarding X-ray activity (Appendix A).
The full list of diagnosis, imaging codes, corresponding modalities
and body sites is available from the authors on request.
2.4. Descriptive statistics
We initially estimated the imaging rate by month (number of ima-
ging tests / number of patients in the cohort) performed in the 12
months before diagnosis, and using Poisson regression, we identified
the likely inflection point at which there was evidence that activity
changed from a background rate (Appendix C). This was around 6
months pre-diagnosis for CT, 7 months for ultrasound and 8 months for
X-ray. For consistency, and so as to not ignore any relevant imaging, an
8-month cut-off was used for all modalities. We then found the first test
in the year before diagnosis, and restricted all subsequent descriptive
analyses to patients with their first test performed up to 8 months pre-
diagnosis.
2.5. Sub-analysis
We performed crude, then adjusted, logistic regression analyses to
examine the association between patient, imaging and tumour vari-
ables, and an index test having occurred between 4–8 months compared
with one occurring 0–3 months pre-diagnosis. We regarded 3 months to
be a conservative cut-off for the duration which one could expect a
patient who had an initial imaging test to be diagnosed with cancer.
Patient variables included gender, age group, and presence/absence
of haematuria before the first imaging request and up to 2 years pre-
diagnosis (based on CPRD records); Index of Multiple Deprivation
quintile; and ethnicity (based on HES records). Haematuria was defined
using clinical Read codes used in previous studies [23,24]. The imaging
characteristics included imaging modality and source of imaging re-
ferral (derived from the DID dataset), and cancer variables (cancer site,
stage at diagnosis, year of diagnosis) were from NCRAS data.
All analyses were performed using STATA v15.
3. Results
2,971 urological cancer patients diagnosed between 1st April 2012
and 31st December 2015 had linked CPRD, NCRAS and HES DID data,
of whom 2,261 (76%) had at least one imaging test in the 12 months
pre-diagnosis. After exclusions (Appendices A and B), a final sample of
1988 patients was included in subsequent analyses. Most patients had
one (39%) or two (35%) scans in the year pre-diagnosis; 3.5% had 5 or
more scans.
3.1. Imaging rate
Imaging rates for all three modalities increased towards diagnosis,
particularly so for ultrasound and CT tests compared with X-rays
(Fig. 1). Poisson regression provided evidence for imaging activity in-
creasing from background rates at about 6 months pre-diagnosis for CT,
7 months pre-diagnosis for ultrasound and 8 months for X-ray (Ap-
pendix C). We therefore used 8 months pre-diagnosis as the earliest pre-
Fig. 1. Incidence rate of imaging test for each of the three imaging modalities
(logarithmic scale).
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diagnosis time point during which relevant imaging tests could possibly
indicate that a potential missed diagnostic opportunity could have oc-
curred.
A Descriptive statistics
3.2. First imaging test
1971 patients had their first imaging tests in the 8 months prior to
diagnosis; among those 11% had an X-ray, 48% an ultrasound, and 41%
a CT as their first requested test (Table 1).
1,543 (79 %) patients had their first imaging test 0–3 months pre-
diagnosis, and 428 (21 %) patients 4–8 months pre-diagnosis; 48%,
43% and 9% of the 4–8 month group had ultrasound, CT scans and X-
rays respectively.
3.3. Imaging request source
Excluding imaging tests that might relate directly to the cancer di-
agnosis itself (those< 1month pre-diagnosis), 305/1,314 (23%) pa-
tients had a first imaging test requested by a GP, and 76% by specialists
in the 18 months pre-diagnosis. The type of requested tests differed by
source: 81 % of GP-requested imaging tests related to an ultrasound,
while in contrast the corresponding figure for requests by specialists
was 45%. The increase in the use of imaging test in the months leading
up to cancer diagnosis was mostly for ultrasound in GP-referred cases,
but the increase was similar for both ultrasound and CT scans in spe-
cialist-referred cases (Fig. 2).
B Additional analyses
Univariable and adjusted analyses provided concordant evidence in
identifying factors associated with first imaging test occurring 4–8
months pre-diagnosis (Table 2).
In the adjusted analyses, patients without haematuria recorded
before the first imaging test had an increased odds of having a first
imaging test 4–8 months pre-diagnosis compared to those with hae-
maturia (adjusted OR 3.02 (CI 2.32–3.95), p< 0.001). Those diagnosed
with kidney or urothelial cell cancer had 2- and 3-fold greater odds,
respectively, of having a test 4–8 months pre-diagnosis compared to
bladder cancer patients (adjusted OR compared with bladder cancer:
2.85 (CI 1.67–4.85) for UUTUCC; 1.75 (CI 1.29–2.37) for kidney
cancer, p< 0.001). Having an X-ray compared to ultrasound and CT as
the first imaging test (adjusted OR 2.89 (CI 1.97–4.22), p< 0.001 X-ray
vs CT), and having a GP-requested (vs specialist-requested) first ima-
ging test (adjusted OR 2.51 (CI 1.88–3.36), p< 0.001 GP vs non-GP)
were also associated with greater likelihood of having a first imaging
test 4–8 months pre-diagnosis. Patients with stage 4 cancer were least
likely to have had a first imaging test 4–8 months pre-diagnosis (ad-
justed OR 0.29 (CI 0.17-0.50), p< 0.001 Stage 4 vs 0).
Given that imaging tests are more likely to be relevant in the context
of kidney compared to bladder cancer (where cystoscopy also plays a
major role in the diagnostic pathway), we examined the frequencies of
imaging type by cancer site in patients with a first imaging test between
4–8 months pre-diagnosis, and the number of patients who had no ul-
trasound or CT scans performed at any point after an initial imaging test
(Table 3).
Among urological cancer patients with an initial imaging test 4–8
months pre-diagnosis, 47%, 46% and 7% were subsequently diagnosed
with bladder, kidney and upper tract urothelial cancer patients re-
spectively. While comparing imaging modality, more than half of
Table 1
Frequency of urological cancer patients’ first imaging tests for each month before diagnosis for all imaging modalities between 0 and 8 months pre-diagnosis.
Month pre-diagnosis X-ray Ultrasound CT any of x-ray/ ultrasound/ct
N % Cum. %a N % Cum. %a N % Cum. % N %
1 66 32 3 249 26 13 334 41 17 649 33
2 50 24 6 311 33 29 253 31 30 614 31
3 23 11 7 173 18 37 84 10 34 280 14
4 13 6 8 94 10 42 49 6 37 156 8
5 14 7 8 48 5 45 31 4 38 93 5
6 12 6 9 31 3 46 11 1 39 54 3
7 9 4 10 25 3 47 24 3 40 58 3
8 20 10 11 20 2 48 19 2 41 59 3
Total 207 951 805 1,963
a Cumulative percentage against whole cohort n = 1,963.
Fig. 2. Number of patients who had each of the three modalities as their first
imaging test in the 8 months before diagnosis by imaging request source (NB.
Please note difference in y-axis scale between figures).
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patients whose first test was an ultrasound were subsequently diag-
nosed with bladder cancer. In contrast, the majority of patients with an
initial CT scan in the 4–8 months pre-diagnosis were subsequently di-
agnosed with kidney cancer (Table 3).
4. Discussion
We found that increased imaging activity occurs in many patients
with urological cancer as early as 8 months before diagnosis. About 1 in
5 of these patients had a first imaging test between 4–8 months pre-
diagnosis, representing a ‘diagnostic window’ period which might have
led to earlier diagnosis. Factors associated with lower specificity of
presentation were associated with increased likelihood of imaging ac-
tivity 4–8 months pre-diagnosis.
Our findings are consistent with existing literature reporting in-
creasing healthcare utilisation (including of diagnostic tests) in the few
months prior to cancer diagnosis [4–6,10,25]. The increase in GP-re-
quested ultrasounds but not GP-requested CTs during in the 8 months
pre-diagnosis likely reflects the availability of direct-access tests for
ultrasound, but not for CT, to GPs in the English NHS.
1 in 5 patients had an imaging test that did not lead to a diagnosis
until 4–8 months later. Potential delays can occur during the testing
phase (i.e. from test request to test performance and reporting) but we
found that the overall test interval from a request to reporting was
generally short (median of 10 days, Appendix D). Delays outside the
testing phase (i.e. from test reporting to diagnosis) could reflect the
ordering of a less appropriate first/subsequent test (pre-analytical test
phase), or missed/ delayed follow-up of a positive test result (post-
analytical test phase) (Box 1) [26]. During the post-analytical phase,
inaccurate, missed, or delayed follow-up of test results are common
[27,28].
Patients without haematuria (an alarm symptom that forms part of
Table 2
Results of logistic regression of association between patient, imaging and cancer variables and the odds of having a first imaging test between 4-8 months (compared
to 0-3 months) pre-diagnosis.







Male 1,345 278 20.7 Reference 0.247 Reference 0.613
Female 618 142 23.0 1.14 (0.91, 1.44) 0.94 (0.73, 1.21)
Age Group
<35 10 4 40.0 2.89 (0.76, 10.95) 0.315 2.74 (0.62, 12.20) 0.248
35-44 49 8 16.3 0.85 (0.36, 2.01) 0.87 (0.34, 2.23)
45-54 144 27 18.8 Reference Reference
55-64 317 76 24.0 1.37 (0.84, 2.23) 1.72 (1.01, 2.94)
65-74 621 140 22.5 1.26 (0.80, 2.00) 1.56 (0.95, 2.57)
75-84 573 121 21.1 1.16 (0.73, 1.85) 1.63 (0.98, 2.71)
85+ 249 44 17.7 0.93 (0.55, 1.58) 1.27 (0.71, 2.26)
Ethnicity
White 1,878 406 21.6 Reference 0.172 Reference 0.318
Asian 21 5 23.8 1.13 (0.41, 3.11) 1.41 (0.48, 4.10)
Black 14 5 35.7 2.01 (0.67, 6.04) 1.43 (0.43, 4.74)
Mixed 4 0 0.0 Omitted Omitted
Other/
Unknown
42 4 9.5 0.38 (0.14, 1.08) 0.39 (0.13, 1.18)
IMD
1 461 96 20.8 1.12 (0.77, 1.63) 0.207 1.34 (0.89, 2.02) 0.432
2 487 103 21.1 1.14 (0.79, 1.65) 1.34 (0.90, 2.01)
3 418 84 20.1 1.07 (0.73, 1.57) 1.19 (0.78, 1.80)
4 324 85 26.2 1.51 (1.02, 2.23) 1.47 (0.96, 2.24)
5 273 52 19.0 Reference Reference
Haematuria
No 1,016 314 30.9 Reference < 0.001 Reference <0.001
Yes 947 106 11.2 3.55 (2.79, 4.52) 3.02 (2.32, 3.95)
Modality
X-ray 207 68 33.3 2.45 (1.74, 3.46) < 0.001 2.89 (1.97, 4.22) <0.001
USS 951 218 22.9 1.49 (1.17, 1.89) 1.34 (1.01, 1.76)
CT 805 134 16.6 Reference Reference
Gp-referred
No 1,616 280 17.3 Reference < 0.001 Reference <0.001
Yes 347 140 40.3 3.23 (2.51, 4.14) 2.51 (1.88, 3.36)
Cancer site
Bladder 1,197 199 16.6 Reference < 0.001 Reference <0.001
Kidney 680 192 28.2 1.97 (1.57, 2.47) 1.75 (1.29, 2.37)
UUTUCC 86 29 33.7 2.55 (1.59, 4.09) 2.85 (1.67, 4.85)
Stage
0 415 74 17.8 Reference < 0.001 Reference <0.001
1 378 102 27.0 1.70 (1.21, 2.39) 1.07 (0.71, 1.60)
2 155 24 15.5 0.84 (0.51, 1.40) 0.65 (0.37, 1.11)
3 160 40 25.0 1.54 (0.99, 2.38) 0.86 (0.51, 1.45)
4 247 31 12.6 0.66 (0.42, 1.04) 0.29 (0.17, 0.50)
Unknown 338 78 23.1 1.38 (0.97, 1.97) 1.08 (0.72, 1.62)
Missing 270 71 26.3 1.64 (1.14, 2.38) 1.02 (0.66, 1.60)
Abbreviations: CI= confidence interval; CT=computed tomography; IMD= index of multiple deprivation; N= number of patients; OR = odds ratio;
USS=ultrasound; UUTUCC= upper urinary tract urothelial cell carcinoma.
All p-values based on joint Wald test of categorical variables.
1 Model also adjusted for year of diagnosis, p-value not significant (results not shown).
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the presenting picture in about 70% of cases with bladder cancer, but
less than a quarter of patients with kidney cancer [23,24]); and those
subsequently diagnosed with kidney cancer were more likely to be at
risk of a potential delayed diagnosis compared to those with haematuria
and subsequently diagnosed with bladder cancer. This supports pre-
vious evidence that patients with non-specific symptoms, and ‘harder-
to-suspect’ cancers (i.e. those where only a small percentage of patients
present with symptoms of relatively high predictive value, in this in-
stance kidney compared to bladder cancer), are more likely to be as-
sociated with diagnostic delay [29]. Our findings suggest in particular
that patients with kidney cancer are more likely to have an initially
non-specific or insensitive imaging test, or the imaging result may be
challenging to interpret, leading to possible diagnostic delay after an
initial imaging test. Patients with Stage 4 cancer are likely to present in
serious clinical condition, prompting fast investigative action leading to
a shorter time to diagnosis. Having an X-ray as an initial imaging test is
associated with a longer time to diagnosis, compared to ultrasound and
CT, as it has limited diagnostic accuracy in urological cancer. The first
imaging tests performed 4–8 months pre-diagnosis were more likely to
be GP-requested, probably due to potential delays in the scheduling,
follow-up and referral processes after an abnormal direct-access ima-
ging test arranged from primary care.
In patients subsequently diagnosed with bladder cancer, about 1 in
2 and 1 in 3 had an initial ultrasound and CT respectively between 4–8
months pre-diagnosis. In these patients, delays in a cystoscopy referral,
or in carrying out the cystoscopy, could be likely explanations for the
prolonged interval to diagnosis, although false reassurance from a false
negative imaging test could also be possible reasons. However, about
55% of cancer patients with a CT and 43% of those with an ultrasound
carried out 4–8 months pre-diagnosis were subsequently diagnosed
with kidney cancer. For this group of patients, cystoscopy referral/
scheduling delays, while possible (e.g. if the wrong urological site is
suspected), are nonetheless less likely as, in most of those cases, it can
be assumed that the presenting symptoms would have not being
pointing to bladder cancer. Diagnostic delays in such cases might arise
from issues during the analytical (test performance, reporting), and/or
the post-analytical test phase (subsequent interpretation, scheduling of
referrals or additional investigations).
4.1. Strengths and limitations
To our knowledge, this is the first study to describe pre-diagnostic
imaging activity in urological cancer patients. We use a novel linked
population-based dataset in a representative population, paving the
way for exploring potential missed diagnostic opportunities in these
patients.
DID contained patient-level information on the exact imaging test
performed, allowing us to consider a ‘relevant’ imaging test depending
on body site, within a time period that we have detected the imaging
activity to be different from background activity. We therefore mini-
mised any bias introduced from irrelevant tests performed in the co-
hort. We regarded the increase in imaging activity during this 0–8
month pre-diagnostic period as a response to relevant (to the subse-
quently diagnosed cancer) clinical symptoms or signs, and assumed that
any potential cancer significant enough to have caused these clinical
symptoms/signs would also be detectable by imaging, or that in the
context of a negative test, alternative effective diagnostic strategies
could have been pursued. These assumptions which underpin the logic
model for our analysis are reasonable, but not certainly applicable to all
patients.
Given the lack of availability of imaging test results in the DID
source, and inability to examine the full medical records of these pa-
tients, we are not able to confidently infer whether among cases with
imaging test 4–8 months pre-diagnosis, there was a missed diagnostic
opportunity in their pathway, only that this could have been possibly
the case. In addition, our source data collected by NHS Digital (the
Diagnostic Imaging Dataset) is a priori excluding non-NHS scans (e.g.
those carried out in private hospitals). The lack of data on private
imaging tests performed may lead to slight underestimation of the true
burden of imaging tests performed 4–8 months pre-diagnosis that may
represent missed opportunities.
4.2. Implications
There is increasing evidence that optimisation of the testing phase
during the diagnostic process is crucial to improving diagnostic quality
and safety, and this includes being able to maintain a vigilant outlook
and avoiding premature diagnostic closure when no firm cause of
symptoms can be found. Further, a test needs to be followed-up and
acted upon after it has been ordered and performed to establish the
findings [30]. Better communication on how to receive and follow-up
the results of tests includes the engagement of patients, primary and
secondary care clinicians [26,31]. For example, patient portals allowing
access to test results are increasingly being advocated to encourage
patient engagement in their own test management and results follow-up
[32]. Research into electronic triggers integrated into computer systems
to remind clinicians to follow-up abnormal results has shown promising
results in the United States, such triggers being able to correctly identify
Table 3
Number of patients who had a first imaging test 4-8 months pre-diagnosis by
cancer site and imaging modality.
Bladder Kidney UUTUCC Total
N % N % N %
First imaging test 4–8 months
pre-diagnosis
199 47.4 192 45.7 29 6.9 420
Patients with the following imaging test
Ultrasound 154 50.8 130 42.9 19 6.3 303
CT 121 37.1 179 54.9 26 8.0 326
Patients with no imaging test
No ultrasound 45 38.5 62 53.0 10 8.5 117
No CT 78 83.0 13 13.8 3 3.2 94
No ultrasound or CT 4 50.0 3 37.5 1 12.5 8
Abbreviation: CT = computed tomography; N = number; UUTUCC = upper
urinary tract urothelial cell cancer.
Box 1
Potential causes of delay in test-to-diagnosis interval relating to the use of test.
• Pre-analytical delays:
o Inappropriate (to the clinical picture) test ordered due to interpretation or clinical reasoning errors
o Test phase delays:
▪ Test scheduling delay
▪ Patient factors: postponing test
• Analytical delays:
o Incorrect reporting of result (false negative or false positive)
• Post-analytical delay:
o Missed or delayed follow-up
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potential missed or delayed follow-up of abnormal test results in up to
60 % of the cases [33].
4.3. Conclusions
We found that diagnostic imaging activity increased from as early as
8 months before a urological cancer diagnosis, indicating that ‘signals’
to expedite the diagnosis of cancer may be detectable in up to 1 in 5
patients. Patients with less specific clinical features were more likely to
have an early imaging test 4–8 months pre-diagnosis. The findings
provide proof of concept that missed diagnostic opportunities, in-
cluding relating to the use of imaging tests, may occur in many patients
with urological cancers, and should stimulate additional inquiry.
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Appendix A. Number of imaging tests performed stratified for each imaging modality and body site in the 12 months before diagnosis
Modality and body site Frequency Percentage Cumulative percentage
Xray
Urinary tract 60 2.41 2.41
Abdomen/ pelvis 466 18.72 21.13
Other sites 1,963 78.87 100
Total 2,489 100
USS
Urinary tract 1,364 76.46 76.46
Abdomen/ pelvis 126 7.06 83.52
Other sites 294 16.48 100
Total 1,784 100
CT
Urinary tract 1,074 38.3 38.3
Abdomen/ pelvis 1,103 39.34 77.64
Other sites 627 22.36 100
Total 2,804 100
MRI
Urinary tract 121 29.09 29.09
Abdomen/ pelvis 65 15.63 44.71
Other sites 230 55.29 100
Total 416 100
Fluoroscopy
Urinary tract 135 40.3 40.3
Abdomen/ pelvis 60 17.91 58.21
Other sites 140 41.79 100
Total 335 100
endoscopy
Urinary tract 17 65.38 65.38
Abdomen/ pelvis 7 26.92 92.31
Other sites 2 7.69 100
Total 26 100
Nuclear medicine
Urinary tract 66 29.07 29.07
Abdomen/ pelvis 109 48.02 77.09
Other sites 52 22.91 100
Total 227 100
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Appendix B. Sample derivation flowchart
Appendix C. Poisson Regression estimates for inflection point for each of the three imaging modalities
In order to estimate the time relative to diagnosis that imaging frequency changed from a background rate, we utilised a series of Poisson
regression models exploring the different possible inflection points. For each imaging mode separately, a model was run for each inflection point
from 4 months to 11 months. In each case the monthly count of imaging was modelled by including a constant term, to account for the background
rate, and a variable equal to the number of months between the inflection point and the month of interest for months closer to diagnosis than the
inflection point and equal to zero otherwise. Data from 1 and 2 months prior to diagnosis were ignored for this analysis due to a levelling off in the
rate of some imaging close to diagnosis. The log-likelihood for each model was recorded and the lowest value was taken to indicate the best fit to the
data. For consistency, and so as to not ignore any relevant imaging, an 8 month cut-off was used for all modalities, being the longest time period
across the three imaging modalities.
Month before diagnosis Log likelihood
X-ray USS CT
4 −32.777 −69.599 −67.229
5 −29.339 −43.949 −40.375
6 −28.113 −35.628 −40.189*
7 −29.426 −34.434* −41.535
8 −29.090* −36.428 −45.151
9 −30.153 −37.766 −47.888
10 −30.677 −41.805 −51.862
11 −31.358 −44.651 −56.032
* Indicates likely inflection point
Appendix D. Test request to reporting interval (total test interval)
We defined the various testing intervals using dates of the testing activities reported in HES DID, as follow:
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a) Request interval: time taken from the imaging request being sent to being received (interval 1)
b) Scheduling interval: time from imaging request being received to imaging being performed (interval 2)
c) Total pre-analytical interval: time taken from imaging request being sent to test performed (intervals 1 + 2)
d) Reporting interval: time taken from test being performed to imaging report being issued (interval 3).
e) Total test interval: time taken from imaging request being sent to report being issued (interval 4 = 1 + 2 + 3)
f) Test-to-diagnosis interval: time from request being sent to cancer diagnosis made (interval 5 = 1 + 2 + 3+4)
Fig. A1.
Mean and Interquartile range of time interval for the testing phases for patients with an initial test 1–8 months pre-diagnosis.
Time interval Test phase No. of Patients Mean (days) InterQuartile Range (days)
10% 25% 50% 75% 90%
Request sent to diagnosis Test to diagnosis 1,314 84 36 44 64 105 170
Request sent to report Test interval 1,314 17 0 2.5 10 21 36
Request sent to test Total pre-analytical 1,314 13 0 1 8 18 34
Request sent to received Pre-analytical (admin) 1,314 1 0 0 0 0 2
Request received to test Pre-analytical (scheduling) 1,314 15 0 1 7 17 33
Test to report Post-analytical (reporting) 1,314 2 0 0 0 2 6
Diagrammatic representation of the median number of days (in ovals) for each test interval
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